The trajectory of companies tied to Viagra's past presents a intricate investment landscape. While the initial surge generated substantial profits , generic competition have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a thorough assessment of intellectual property protection , evolving medical shifts ,